Dr. Richard Pazdur Calls for Fundamental Reinvention of FDA Oncology Oversight

Dr. Richard Pazdur, the long-standing director of the FDA’s Oncology Center of Excellence, has issued a stark warning regarding the future of the agency. After two decades of overseeing transformative cancer therapy approvals, Pazdur suggests the FDA has reached a critical point of institutional exhaustion. Rather than focusing on individual clinical outcomes, his critique addresses the structural integrity and long-term viability of the agency amidst accelerating technological breakthroughs and intensifying global competition. Pazdur characterizes the current regulatory environment as one of systemic destruction, arguing that the traditional bureaucratic framework is no longer sufficient to meet modern demands. His appeal highlights a desperate need for a foundational reinvention of the FDA to ensure that the United States maintains its leadership in medical innovation. As the agency faces internal upheaval, the central question remains whether it can successfully undergo a structural metamorphosis or if it will continue to struggle against an outdated regulatory model. This call to action signals a potential turning point for oncology regulation and the broader mission of the Food and Drug Administration in the coming years.